Matthew Maxwell Donley's Net Worth
$5.42 Million
Who is Matthew Maxwell Donley?
Matthew Maxwell Donley has an estimated net worth of $5.42 Million. This is based on reported shares across multiple companies, which include Aurinia Pharmaceuticals Inc., and Sucampo Pharmaceuticals, Inc..
SEC CIK
Matthew Maxwell Donley's CIK is 0001636642
Past Insider Trading and Trends
2017 was Matthew Maxwell Donley's most active year for acquiring shares with 6 total transactions. Matthew Maxwell Donley's most active month to acquire stocks was the month of February. 2018 was Matthew Maxwell Donley's most active year for disposing of shares, totalling 6 transactions. Matthew Maxwell Donley's most active month to dispose stocks was the month of January. 2021 saw Matthew Maxwell Donley paying a total of $99,738.54 for 9,900 shares, this is the most they've acquired in one year. In 2018 Matthew Maxwell Donley cashed out on 415,975 shares for a total of $3,561,990.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Aurinia Pharmaceuticals Inc. (AUPH) Snapshot price: $7.4
EVP, Ops & StrategyMatthew Maxwell Donley owns 584,072 units of Common Stock which is worth $4,322,132.80. From 2022 to 2024 Matthew Maxwell Donley acquired a total of 516,200 shares in Aurinia Pharmaceuticals Inc. at a cost of $146,338.54, Matthew also disposed a total of 43,717 shares of Aurinia Pharmaceuticals Inc. equalling to $260,718.67.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -6.51% | -40.66K |
$5.51 | -$224,064.15 | 584.07K |
Mar 6
| |||
Form 4
| +53.10% | 216.67K |
—
|
—
| 624.74K |
Feb 20
| |||
Form 4
| +205.39% | 271.13K |
—
|
—
| 403.14K |
Mar 2
| |||
Form 4
| +55.78% | 10K |
$4.66 | $46,600.00 | 27.93K |
Nov 21
| |||
Form 4
| +50.56% | 5.45K |
$12.01 | -$36,654.52 | 16.22K |
Mar 2
| |||
Form 4
|
∞
| 9.9K |
$10.07 | $99,738.54 | 9.9K |
May 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Sucampo Pharmaceuticals, Inc. No price found
EVP, Global HR, IT & StrategyMatthew Maxwell Donley owns 36,975 units of Common Stock, Class A (ESPP), 53,000 units of Common stock and 36,975 units of Common Stock, Class A. In the year 2015 Matthew Maxwell Donley filed a total of 15 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -50.00% | -36.98K |
$18.00 | -$665,550.00 | 36.98K |
Feb 13
| |||
Form 4
| +0.90% | 330 |
$9.10 | $3,003.00 | 36.98K |
Dec 31
| |||
Form 4
| -34.56% | -19.35K |
$17.98 | -$347,966.94 | 36.65K |
Dec 28
| |||
Form 4
| +12.37% | 330 |
$9.10 | $3,003.00 | 3K |
Sep 30
| |||
Form 4
| +14.41% | 336 |
$8.93 | $3,000.48 | 2.67K |
Jun 30
| |||
Form 4
| +15.96% | 321 |
$9.35 | $3,001.35 | 2.33K |
Mar 31
| |||
Form 4
|
∞
| 53K |
—
|
—
| 53K |
Mar 6
| |||
Form 4
| +16.58% | 286 |
$10.46 | $2,991.56 | 2.01K |
Dec 31
| |||
Form 4
| +22.78% | 320 |
$9.38 | $3,001.60 | 1.73K |
Sep 30
| |||
Form 4
| +36.54% | 376 |
$9.32 | $3,504.32 | 1.41K |
Mar 31
| |||
Form 4
| +45.75% | 323 |
$9.29 | $3,000.67 | 1.03K |
Mar 31
| |||
Form 4
| +50.85% | 238 |
$14.70 | $3,498.60 | 706 |
Dec 31 - Mar 2
| |||
Form 4
|
∞
| 468 |
$13.88 | $6,495.21 | 468 |
Jun 30 - Sep 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||